vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
Zeo Energy Corp. is the larger business by last-quarter revenue ($18.6M vs $9.3M, roughly 2.0× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -10.8%, a 11.4% gap on every dollar of revenue. On growth, Zeo Energy Corp. posted the faster year-over-year revenue change (-0.4% vs -3.0%). Zeo Energy Corp. produced more free cash flow last quarter ($2.3M vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -4.0%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
SSKN vs ZEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $18.6M |
| Net Profit | $58.0K | $-2.0M |
| Gross Margin | 61.8% | — |
| Operating Margin | 5.3% | -11.8% |
| Net Margin | 0.6% | -10.8% |
| Revenue YoY | -3.0% | -0.4% |
| Net Profit YoY | 101.3% | -360.9% |
| EPS (diluted) | $0.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $18.6M | ||
| Q3 25 | $6.9M | $23.9M | ||
| Q2 25 | $7.7M | $18.1M | ||
| Q1 25 | $6.8M | $8.8M | ||
| Q4 24 | $9.6M | $18.6M | ||
| Q3 24 | $8.8M | $19.7M | ||
| Q2 24 | $8.4M | $14.8M | ||
| Q1 24 | $6.8M | $20.1M |
| Q4 25 | $58.0K | $-2.0M | ||
| Q3 25 | $-1.6M | $-3.2M | ||
| Q2 25 | $-2.6M | $-2.4M | ||
| Q1 25 | $-2.1M | $-6.4M | ||
| Q4 24 | $-4.6M | $-435.3K | ||
| Q3 24 | $-2.1M | $-424.3K | ||
| Q2 24 | $-91.0K | $-277.8K | ||
| Q1 24 | $-3.4M | $-1.5M |
| Q4 25 | 61.8% | — | ||
| Q3 25 | 60.4% | 57.9% | ||
| Q2 25 | 56.2% | 59.8% | ||
| Q1 25 | 53.5% | 99.3% | ||
| Q4 24 | 61.4% | — | ||
| Q3 24 | 60.1% | 50.2% | ||
| Q2 24 | 59.0% | 52.3% | ||
| Q1 24 | 45.6% | — |
| Q4 25 | 5.3% | -11.8% | ||
| Q3 25 | -16.9% | -8.3% | ||
| Q2 25 | -30.1% | -15.8% | ||
| Q1 25 | -25.0% | -153.8% | ||
| Q4 24 | -44.7% | -6.0% | ||
| Q3 24 | -18.2% | -15.2% | ||
| Q2 24 | -5.7% | -18.0% | ||
| Q1 24 | -42.7% | -20.1% |
| Q4 25 | 0.6% | -10.8% | ||
| Q3 25 | -23.4% | -13.5% | ||
| Q2 25 | -33.6% | -13.3% | ||
| Q1 25 | -31.2% | -72.4% | ||
| Q4 24 | -47.6% | -2.3% | ||
| Q3 24 | -23.6% | -2.2% | ||
| Q2 24 | -1.1% | -1.9% | ||
| Q1 24 | -49.8% | -7.6% |
| Q4 25 | $0.14 | — | ||
| Q3 25 | $-0.36 | — | ||
| Q2 25 | $-0.62 | — | ||
| Q1 25 | $-0.51 | $-0.48 | ||
| Q4 24 | $-2.01 | $1.11 | ||
| Q3 24 | $-0.51 | $-0.08 | ||
| Q2 24 | $-0.03 | $0.03 | ||
| Q1 24 | $-0.10 | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $6.1M |
| Total DebtLower is stronger | $15.3M | $79.1K |
| Stockholders' EquityBook value | $2.9M | $5.3M |
| Total Assets | $30.5M | $56.9M |
| Debt / EquityLower = less leverage | 5.28× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $6.1M | ||
| Q3 25 | $7.1M | $3.9M | ||
| Q2 25 | $6.0M | $68.7K | ||
| Q1 25 | $6.5M | $2.9M | ||
| Q4 24 | $7.3M | $5.6M | ||
| Q3 24 | $7.1M | $4.3M | ||
| Q2 24 | $5.5M | $5.3M | ||
| Q1 24 | $5.2M | — |
| Q4 25 | $15.3M | $79.1K | ||
| Q3 25 | $15.3M | $84.6K | ||
| Q2 25 | $15.0M | $642.8K | ||
| Q1 25 | $15.0M | $715.4K | ||
| Q4 24 | $15.0M | $787.7K | ||
| Q3 24 | $15.0M | $858.6K | ||
| Q2 24 | $15.0M | $1.6M | ||
| Q1 24 | $15.0M | $748.8K |
| Q4 25 | $2.9M | $5.3M | ||
| Q3 25 | $1.3M | $-1.7M | ||
| Q2 25 | $532.0K | $-59.4M | ||
| Q1 25 | $3.0M | $-23.1M | ||
| Q4 24 | $5.0M | $-88.9M | ||
| Q3 24 | $9.4M | $-39.3M | ||
| Q2 24 | $9.5M | $-53.0M | ||
| Q1 24 | $9.4M | $-173.0M |
| Q4 25 | $30.5M | $56.9M | ||
| Q3 25 | $30.7M | $58.5M | ||
| Q2 25 | $29.5M | $46.2M | ||
| Q1 25 | $33.0M | $47.4M | ||
| Q4 24 | $34.9M | $61.0M | ||
| Q3 24 | $39.4M | $47.1M | ||
| Q2 24 | $38.8M | $49.1M | ||
| Q1 24 | $39.2M | $50.1M |
| Q4 25 | 5.28× | 0.01× | ||
| Q3 25 | 11.65× | — | ||
| Q2 25 | 28.20× | — | ||
| Q1 25 | 5.04× | — | ||
| Q4 24 | 3.02× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 1.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $2.4M |
| Free Cash FlowOCF − Capex | $-551.0K | $2.3M |
| FCF MarginFCF / Revenue | -5.9% | 12.2% |
| Capex IntensityCapex / Revenue | 3.4% | 0.9% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $2.4M | ||
| Q3 25 | $-64.0K | $-6.6M | ||
| Q2 25 | $-1.9M | $-2.3M | ||
| Q1 25 | $-550.0K | $-2.3M | ||
| Q4 24 | $703.0K | $3.5M | ||
| Q3 24 | $-302.0K | $162.2K | ||
| Q2 24 | $591.0K | $-2.2M | ||
| Q1 24 | $-804.0K | $-10.2M |
| Q4 25 | $-551.0K | $2.3M | ||
| Q3 25 | $-1.1M | $-6.8M | ||
| Q2 25 | $-2.0M | $-2.7M | ||
| Q1 25 | $-749.0K | $-2.6M | ||
| Q4 24 | $199.0K | $3.4M | ||
| Q3 24 | $-364.0K | $116.5K | ||
| Q2 24 | $246.0K | $-2.3M | ||
| Q1 24 | $-1.5M | $-10.4M |
| Q4 25 | -5.9% | 12.2% | ||
| Q3 25 | -15.6% | -28.6% | ||
| Q2 25 | -26.1% | -15.0% | ||
| Q1 25 | -11.0% | -30.0% | ||
| Q4 24 | 2.1% | 18.2% | ||
| Q3 24 | -4.1% | 0.6% | ||
| Q2 24 | 2.9% | -15.6% | ||
| Q1 24 | -22.6% | -51.5% |
| Q4 25 | 3.4% | 0.9% | ||
| Q3 25 | 14.7% | 1.0% | ||
| Q2 25 | 0.8% | 2.4% | ||
| Q1 25 | 2.9% | 4.2% | ||
| Q4 24 | 5.3% | 0.5% | ||
| Q3 24 | 0.7% | 0.2% | ||
| Q2 24 | 4.1% | 0.7% | ||
| Q1 24 | 10.7% | 1.1% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
